In AML, DNMT3A mutations were observed to occur at frequencies between 20 and 30% depending on the cytogenetic risk group, while in PTCL, it was observed that DNMT3A mutations occur more frequently in AITL compared to other subtypes of PTCL, at approximately 30% of the cases with a significant overlap with TET2 mutations, while in PTCL-NOS or PTCL-NOS TFH, they occur between 4 and 10% [3,10,11,89]. Here, TET2 is linked to acute myeloid leukemia.